undamentalytics Newsletter
Sign in

Precision Biosciences Inc balance sheet

At the end of fiscal 2025, Precision Biosciences Inc had total assets of $154m, total liabilities of $62.2m and shareholders' equity of $92.2m. It held $111m in cash against $0 of debt: net cash of $111m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents103181901441901178611182
Receivables1110011000
Total current assets1161941061621991369511987
Total assets139235150211238160136154120
Accounts payable221113101
Deferred revenue (current)8163021461230—
Total current liabilities1427433660501598
Long-term debt———222————
Total debt000222—000
Total liabilities9997106120178141806269
Shareholders' equity4013844916019569252
Net debt (negative = net cash)−103−181−90−141−167−117−86−111−82
Shares outstanding—————4m8m—28m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: DTIL vs STRODTIL vs SPRODTIL vs EDIT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Precision Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Precision Biosciences Inc.